Project Details


Our overall objectives are to improve the way we treat sufferers with unexplained inflammation in muscle (myositis), by bringing together UK experts, increasing awareness of myositis in the health-care community, improving the way we diagnose myositis, and enhancing health-care professionals training.

Unexplained inflammation in muscle, known as “myositis”, represents a difficult group of related disease, affecting about 10,000 people in the UK. Unlike other muscle diseases such as muscular dystrophy, myositis can be treated. Myositis can also affect internal organs including the heart, lungs and gut. Treatments for myositis can have a lot of side effects and are not always effective. Doctors may not be familiar with recognising the signs of myositis, especially in children. Delays in the diagnosis may lead to irreversible muscle damage; therefore sufferers often remain weak and disabled, leading to a significant burden for carers, parents and society.
Even between experts, there is lack of agreement how to diagnose and treat myositis. The diagnosis can be made by taking a muscle biopsy. The way these biopsies are interpreted varies widely between hospital laboratories and can lead to a wrong diagnosis being made. For example, an incorrect diagnosis of myositis can be made when the correct diagnosis is actually muscular dystrophy, where the potentially toxic treatments for myositis are inappropriate and will not help.
Current treatments are mostly borrowed from related musculoskeletal diseases. There is no national or even international guidance about which treatments to use and at what point in the disease. The fact that drugs for myositis work so poorly reflects our lack of understanding of what causes the disease, and this ignorance has slowed down the development of more effective new drugs. To improve future myositis treatments, a better understanding of what actually causes these diseases is urgently required so that new and more effective drugs can be developed.

Key findings

Our group has published extensively on myositis epidemiology, genetics and genomics, serology and imaging. The Manchester Myositis Research Group is the lead centre for UKMYONET, a community of myositis researchers in the UK, and the EuroMyositis Registry, the largest international myositis registry.
Effective start/end date1/01/10 → …

Collaborative partners

  • The University of Manchester (lead)
  • University of Liverpool (Collaborator)
  • University of Bath (Collaborator)
  • UKMYONET (Collaborator)
  • Myositis UK (Collaborator)
  • EuroMyositis (Collaborator)
  • MYOGEN (Collaborator)

UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being


  • Myositis
  • Idiopathic Inflammatory Myopathy
  • Genetics and genomics
  • Serology
  • Muscle Imaging
  • mHealth
  • Registries
  • Epidemiology

Research Beacons, Institutes and Platforms

  • Manchester Regenerative Medicine Network
  • Lydia Becker Institute


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.